Phenotypic characterization of an older adult male with late-onset epilepsy and a novel mutation in ASXL3 shows overlap with the associated Bainbridge-Ropers syndrome by Verhoeven, W.M.A. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/190577
 
 
 
Please be advised that this information was generated on 2018-05-01 and may be subject to
change.
© 2018 Verhoeven et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php 
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you 
hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission 
for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Neuropsychiatric Disease and Treatment 2018:14 867–870
Neuropsychiatric Disease and Treatment Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
867
C a s e  r e p o rT
open access to scientific and medical research
open access Full Text article
http://dx.doi.org/10.2147/NDT.S153511
phenotypic characterization of an older adult male 
with late-onset epilepsy and a novel mutation 
in ASXL3 shows overlap with the associated 
Bainbridge-ropers syndrome
Willem Verhoeven1,2
Jos egger1,3
emmy räkers4
arjen van erkelens5
rolph pfundt5
Marjolein H Willemsen5
1Vincent van Gogh Institute for 
psychiatry, Centre of excellence 
for Neuropsychiatry, Venray, the 
Netherlands; 2Department of 
psychiatry, erasmus University Medical 
Centre, rotterdam, the Netherlands; 
3Donders Institute for Brain, 
Cognition and Behaviour, radboud 
University, Nijmegen, the Netherlands; 
4asVZ, Centre for people with 
Intellectual Disabilities, sliedrecht, the 
Netherlands; 5Department of Human 
Genetics, radboud University Medical 
Centre, Nijmegen, the Netherlands
Abstract: The additional sex combs like 3 gene is considered to be causative for the rare 
Bainbridge-Ropers syndrome (BRPS), which is characterized by severe intellectual disability, 
neonatal hypotonia, nearly absent development of speech and language as well as several facial 
dysmorphisms. Apart from disruptive autistiform behaviors, sleep disturbances and epileptic 
phenomena may be present. Here, a 47-year-old severely intellectually disabled male is described 
in whom exome sequencing disclosed a novel heterozygous frameshift mutation in the ASXL3 
gene leading to a premature stopcodon in the last part of the last exon. Mutations in this very 
end 3′ of the gene have not been reported before in BRPS. The phenotypical presentation of the 
patient including partially therapy-resistant epilepsy starting in later adulthood shows overlap 
with BRPS, and it was therefore concluded that the phenotype is likely explained by the identi-
fied mutation in ASXL3.
Keywords: Bainbridge-Ropers syndrome, ASLX3, frameshift mutation, epilepsy, intellectual 
disability, array analysis, whole exome sequencing, autism spectrum disorder
Introduction
Bainbridge-Ropers syndrome (BRPS) [OMIM #615485] is a novel syndromal entity 
that is caused by a mutation in the additional sex combs like 3 (ASLX3) gene located 
at 18q12.1. In 2013, the syndrome was first described in four patients.1 The ASLX3 
gene has a functional role in the process of deubiquitination and is expressed in sev-
eral organ systems including the central nervous system.2 At present, 30 patients 
with this syndrome, children and adolescents only, have been published.1,3–6 The 
phenotype typically includes severe intellectual disability, nearly absent speech 
and language, hypotonia, and feeding difficulties at young age as well as distinct 
craniofacial features such as prominent forehead, arched eyebrows, and hyper-
telorism. Regarding behavior, in addition to aggressive and autistic traits with 
rocking and hand flapping, periodic agitation and sleep disturbances are frequently 
described. In a minority of the patients, tonic-clonic seizures or absences occur in 
childhood.5–7
Here, the first middle-aged male patient with a mutation in ASXL3 and a phenotype 
reminiscent of BRPS is described. He developed tonic-clonic epilepsy at the end of 
his fourth decade.
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Patients and methods
Case description
The patient is a 47-year-old male with one older sister by 4 years 
from the same parents, two half-brothers and one half-sister 
from other fathers. All siblings, including most probably 
also their mother, were intellectually disabled and developed 
within a very poor pedagogic family context. Apart from 
minimal to absent speech and language development, no 
information is available about his early years. From the age 
of 6, the patient needed a specialized child day care facility. 
Two years later, he had to be institutionalized because of 
severe behavioral problems, particularly continuous extreme 
screaming, also nocturnal. From his early adolescence on, 
anxious, aggressive, self-injurious, and compulsive behav-
iors occurred intermittently contingent upon environmental 
changes for which various psychotropics were prescribed 
symptomatically. Social maturity was established at a devel-
opmental level of ~5 years. At his mid-thirties, the behavioral 
pattern was attributed to an autism spectrum disorder for 
which he was moved to a specialized ward. This resulted 
in a significant amelioration of his behavioral repertoire. 
Aged 38, the patient developed erythema migrans due to a 
borrelia infection that was proven by seroconversion in blood 
with normal cerebrospinal fluid parameters for which he was 
adequately treated with antibiotics.
At the age of 45 years, the patient’s actions became 
increasingly disruptive with progressive repetitive and 
compulsive behaviors. In addition, intensified sensitivity to 
sensory stimuli as well as severe sleep problems developed 
for which risperidone and lorazepam were prescribed. In this 
period, generalized epilepsy with three tonic-clonic seizures 
occurred and treatment with carbamazepine was started 
(800 mg; 8.7 mg/L). Subsequently, two consecutive 24 h 
video-EEG registrations disclosed no epileptic configura-
tions. CT and MRI scanning of the brain, the latter under 
general anesthesia because of his disinhibited behaviors, 
disclosed no abnormalities. Because of accumulation of 
severe challenging behaviors and sleep disturbances neces-
sitating nearly permanent individualized care, the patient was 
referred for expert consultation.
relevant family context
The patient’s older sister, with about a similar history and 
later staying at the same institute, was institutionalized from 
early age on because of severe challenging behaviors. She 
was also suffering from tonic-clonic seizures, most prob-
ably starting in infancy, for which she was initially treated 
with phenytoine, which was changed to carbamazepine 
(1,000 mg) in her early twenties. There were no neurological 
abnormalities or notable dysmorphic features. Development 
of speech and language was restricted to single words and 
sounds. She displayed autistic traits with periodic screaming, 
crying, and anxiety-driven aggressive behaviors. At that time, 
mean developmental age was 2.5 years. Because of persistent 
epileptic phenomena, occurring also at night, 10 years later 
valproic acid was added (1,200 mg), which, however, could 
not prevent further tonic-clonic seizures. Aged 35 years, 
she underwent bilateral mastectomy because of carcinoma. 
One year later, she died during a nocturnal tonic-clonic 
epileptic status.
The mother of both siblings deceased 4 years later 
(unknown cause). Their father died many years before. 
Similar to the early years of the patient and his sister, no 
additional information is available for both parents.
Results
At examination by a clinical geneticist, a severe intellectually 
disabled, middle-aged male patient was seen with only mild 
facial dysmorphisms (Figure 1). Height, weight, and head 
circumference were 168 cm (−2 SD), 54 kg (BMI: 19), and 
Figure 1 Clinical photograph of the present patient showing mild facial dysmorphic 
features, including deeply set eyes and a prominent nose with high nasal bridge, 
possibly fitting within the spectrum of facial dysmorphic features in BRPS.
Note: They are, however, neither very specific nor easily recognizable.
Abbreviation: Brps, Bainbridge-ropers syndrome.
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53.5 cm (−2.5 SD), respectively. Somatic and neurological 
examination disclosed no abnormalities. Relevant hemato-
logical and biochemical parameters were all normal. His 
behavior repertoire was evaluated by a neuropsychiatrist and 
could be best typified by autistic-like repetitive and com-
pulsive behaviors such as rubbing/stroking and licking with 
increase in unknown situations. Hardly any communication 
was possible but, based on nonverbal instructions, the patient 
was able to perform very simple daily activities, for example, 
bringing his plate to the table and taking his meal.
Since etiological investigation was not performed as yet, 
first, chromosomal analysis using the CytoScan HD array 
(Applied Biosystems™, Foster City, CA, USA) was done, 
which disclosed no abnormalities. Fragile-X syndrome was 
also excluded by DNA diagnostics. Subsequently, whole 
exome sequencing was performed essentially as described 
before.8 Target regions were enriched using the Agilent 
SureSelectXT Human All Exon 50Mb Kit. Whole-exome 
sequencing was performed on the Illumina HiSeq platform 
(BGI, Copenhagen, Denmark) followed by analysis of the 
variants in genes involved in neurodevelopmental diseases. 
Data were analyzed with Burrows-Wheeler Aligner (read 
alignment) and Genome Analysis Toolkit (variant calling) 
software packages. Variants were annotated using an in-house 
developed pipeline. Prioritization of variants was done by an 
in-house designed “variant interface” and manual curation. 
This revealed a heterozygous frameshift mutation in the 
ASXL3 gene: (Chr18(GRCh37):g.31326509_31326522du
p; NM_030632.1:c.6697_6710dup(p.(Ser2238fs)).
It concerns a duplication of 14 base pairs leading to a 
frameshift and premature stop in the 3′-part of the last exon 
of the ASXL3 gene. This will probably lead to the pres-
ence of a truncated protein, rather than nonsense-mediated 
decay and haploinsufficiency. Other reported mutations in 
patients with BRPS are most likely leading to haploinsuf-
ficiency, although the vast majority of the mutations that 
have been described so far are located in the last two exons 
of the ASXL3 gene (The Human Gene Mutation Database).9 
Pathogenic mutations in this very end 3′ of the gene have not 
been reported before. Also, the mutation has been reported 
neither in the previous literature nor in the Exome Aggrega-
tion Consortium (ExAC; http://exac.broadinstitue.org) or 
Genome Aggregation Database (gnomAD; http://gnomad.
broadinstitute.org). It was classified as possibly pathogenic 
since the phenotype of the patient, although not highly spe-
cific but including intellectual disability, the above-described 
speech/language impairment, sleep disturbances, behavioral 
phenomena, and epilepsy, could fit within the spectrum of 
BRPS. Thus, the ASXL3 mutation was concluded to be a 
likely explanation. In addition, it is possible that mutations 
in ASXL3 with another effect than haploinsufficiency may 
lead to phenotypes with intellectual disabilities that are not 
typically fitting into the phenotype of BRPS.
To further specify the phenotypic presentation, extensive 
neuropsychological assessment was performed showing a dis-
crepant profile with a developmental age ranging from 1 year 
(social and communicative skills; Vineland Screener,10 SRZ-
P,11) to maximally 2.5 years (visuomotor functioning; Beery 
VMI12). Due to major impairments in communication, formal 
testing of attention, memory, and executive functioning could 
not be performed. Instead, relevant domains were objecti-
vated by proxy-ratings of attention/executive functioning 
(DEX13 and EFI14: severely disturbed) and psychopathology 
(PIMRA15: anxiety bound symptoms).
Since no appropriate plasma concentration of risperi-
done could be achieved due to enzymatic induction by the 
previously mentioned antiepileptic carbamazepine, the latter 
was replaced by valproic acid. Also, zopiclone was added to 
lorazepam, which to some extent improved his sleep pattern. 
Concerning epilepsy, since the start of antiepileptic drugs, 
tonic-clonic seizures did no longer occur although regular 
daytime absences were still noticed. At present, the patient 
is treated with 1,200 mg valproic acid (60 mg/L), 5 mg 
risperidone (2.8/29 μg/L), 3.5 mg lorazepam (28 μg/L), and 
7.5 mg zopiclone.
Discussion
In this paper, the first middle-aged male patient is described 
in whom whole exome sequencing demonstrated a never 
reported novel frameshift mutation in the ASXL3 gene 
(c.6697_6710dup). Although never reported before and 
located in the very 3′ end of the gene, this mutation was 
considered to be likely pathogenic since the phenotype shows 
overlap with the phenotypic spectrum of BRPS, including 
severe intellectual disability, autistic-like behavioral prob-
lems, and epilepsy that is reported in a minority of the patients 
diagnosed with BRPS. The facial phenotype is not typically 
recognizable as BRPS but the phenotype in other patients 
with this syndrome is variable and not highly specific.6 There 
are, however, some similarities, for example, in the shape of 
the nose that can also be recognized in the present patient 
(Figure 1). It might be that the mutation in the very 3′ end 
of the ASXL3 gene leads to a less “typical” presentation of 
BRPS which, however, is not an easily recognizable syn-
drome per se.6 Furthermore, since individuals with BRPS, in 
particular adults, are relatively rare, the clinical spectrum may 
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be actually much broader than reported up to now. In contrast 
to his deceased sister, his epilepsy started not at an early age 
but in his fourth decade and is partially therapy resistant since 
absences still persist. However, given the developmental 
issues, presentation, and course of disease including severe 
epilepsy, his deceased sister could have had the same genetic 
disorder. In both, social interaction could be characterized 
as predominantly anxiety-driven disruptive autistiform 
behaviors. Since intellectual disability was reported in the 
mother as well, the mutation in ASXL3 might be inherited 
from her. Perhaps, she was more mildly affected due to the 
presence of the mutation in mosaic state. However, half-
siblings with the same father were also reported to have 
intellectual disability. Since segregation analysis was not pos-
sible and detailed clinical data are lacking, it remains unclear 
whether this mutation is inherited and if so, from whom.
Conclusion
Extensive genetic analysis including whole exome sequenc-
ing is mandatory in patients with unexplained developmental 
delay and intellectual disability, also in adulthood and older 
age. The latter not only to detect the genetic etiology of syn-
dromic intellectual disability, but especially also to further 
elucidate course into adulthood and prognosis of newly 
discovered disorders like Bainbridge-Ropers syndrome.
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